☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Disorder
BMS Signs an Agreement with BioMotiv to Develop Therapies for Patients with Serious Disorder
September 4, 2019
Alexion's Soliris (eculizumab) Receives FDA's Approval for Anti-Aquaporin-4 Antibody Positive Patients with Neuromyelitis Optica S...
June 28, 2019
Load more...
Back to Home